Theratechnologies reports Q2 revenue $15.6M vs. $9.6M last year
"The Company continues to deliver sustained growth while giving itself the tools and levers to achieve its vision of becoming a significant player in the pharmaceutical industry. Shortly, we expect a recommendation from the CHMP for Trogarzo in Europe and the launch of the new EGRIFTA SV in the United States. This could help give the Company even more momentum in the coming years as we keep working on the development of extremely exciting longer-term projects," said CEO Luc Tanguay. "Among them, the development of a new formulation of EGRIFTA in NASH-HIV which, based on early market research, represents an estimated total population between 100,000 to 300,000 patients, and our targeted oncology platform for which we will pursue two initial indications in ovarian and triple-negative breast cancer."